Novo Nordisk looks into starting GLP-1 drug trials for addiction

Novo Nordisk is considering investigating its GLP-1 therapies in the treatment of addictions, mirroring similar comments made by its major incretin rival Eli Lilly. Novo is already studying its GLP-1 agonist semaglutide, along with a ...

Related Posts

Eli Lilly inks $630M deal for Phase 1 MASH candidate

Feb 10, 2025  0

Lilly pays $10M upfront for Organovo’s FXR agonist program

Feb 25, 2025  0

Eli Lilly expands Zepbound single-dose vial options at ...

Feb 25, 2025  0

Comments

Name

Email

Comment

Post Comment